A Pilot Study to Examine the Correlation between Cognition and Blood Biomarkers in a Singapore Chinese Male Cohort with Type 2 Diabetes Mellitus

Abstract

BackgroundDiabetes is reported to be linked to poorer cognitive function. The purpose of this study is to examine (a) clinical correlation between cognitive function and the biochemical perturbations in T2DM, and (b) the impact of statin treatment on cognitive function in diabetic subjects.MethodsForty Singaporean Chinese males with diabetes and twenty Singaporean Chinese males without diabetes were recruited for this study. Twenty-two of the diabetic subjects were on statin therapy and all subjects were non-demented. This was a 2-period non-interventional case-control study in which subjects were assessed for cognitive function in period 1 and blood samples taken over 2 periods, approximately 1 week apart. Blood was collected to determine the level of total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, glucose and insulin. Cognitive performance was measured by a neuropsychological battery covering domains of attention, language, verbal and visual memory, visuomotor speed and executive function. Z-scores were derived for each cognitive domain using the mean and standard deviations (SDs), and they were used to compare between (a) diabetic and non-diabetic groups, and (b) diabetic subjects with and without statin treatment. ANCOVAs with age, education, BMI, and the duration of diabetes as covariates were employed to examine differences in mean score of cognitive domains and subtests between the two groups.ResultsOverall cognitive function was similar among diabetics and age matched non-diabetic controls. Among diabetic statin users, HDL, LDL and total cholesterol were negatively correlated with executive function, whereas peripheral insulin levels and insulin resistance were negatively associated with attention.ConclusionDiabetic statin users were likely to have poorer performance in attention and executive function. Increasing levels of the peripheral biomarkers are likely to contribute to poorer cognitive performance.

Prevalence of Cognitive Impairment in Recently Diagnosed Type 2 Diabetes Patients: Are Chronic Inflammatory Diseases Responsible for Cognitive Decline?

“…A possible explanation for this difference may be the ages of the patients included in the analyses, as the patients in our study were relatively young. For example, the estimated prevalence of CI among patients ≥ 65 years old is 7% in Mexico and may vary between 3% and 5.9% in Latin America [ 30 ]; and the relatively low prevalence of CI noted among the patients with T2D in our study is consistent with the results of studies analyzing younger patient cohorts [ 31 ]. However, the prevalence noted in the present study was higher than expected for a group of patients with an average age of 50 years.…”

Serum high‐density lipoprotein cholesterol is a protective predictor of executive function in older patients with diabetes mellitus

“…This suggests that serum HDL‐C is specifically associated with executive function in older people with diabetes mellitus. A case–control study found a positive association between HDL‐C levels and executive function in the diabetic statin users, but not in non‐users. A longitudinal study in France reported that lower HDL‐C was associated with an increased risk of cognitive decline in executive function and psychomotor speed in older men.…”

Diabetes is Associated with Worse Executive Function in Both Eastern and Western Populations: Shanghai Aging Study and Mayo Clinic Study of Aging

“…In contrast to these studies that used a single test to assess executive function, we measured executive function from a composite of two tests. Another study showed no differences in cognitive measures in diabetic and non-diabetic controls, however, diabetic statin users had worse performance on tests of executive function, suggesting potentially worse vascular disease that could impact executive function [34]. Previous reports on neuropsychological testing in DM versus non-DM have varied from comparisons of a single test [35, 36] to a comprehensive battery [37–39].…”